Servier is licensing cancer drug treatment software from US start - up CureMatch . “That led to some additional meetings, which led to a due diligence process that was very rigorous and length,” Manning says. The latter , PreciGENE , helps oncologists configure suitable combinations of drugs to give patients information on cancer DNA mutations . While the digital health firm has grown since launching in November 2014 , it said the French pharmaceutical company ’s involvement had given it a vital financial boost . The undisclosed deal sees Servier gain exclusive rights to sell access to CureMatch ’s platform across its worldwide network of clinics and hospitals . CureMatch will receive help expanding sales and marketing , while providing assistance in its clinical trial and software development programmes .
Servier is licensing cancer drug treatment software from US start - up CureMatch . The latter , PreciGENE , helps oncologists configure suitable combinations of drugs to give patients information on cancer DNA mutations . While the digital health firm has grown since launching in November 2014 , it said the French pharmaceutical company ’s involvement had given it a vital financial boost . The undisclosed deal sees Servier gain exclusive rights to sell access to CureMatch ’s platform across its worldwide network of clinics and hospitals . CureMatch will receive help expanding sales and marketing , while providing assistance in its clinical trial and software development programmes .